Trial Profile
A study of Blinatumomab therapy for relapsed/refractory acute lymphoblastic leukaemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 04 Dec 2018 Results (n=29) characterizing genomic features associated with response to blinatumomab presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 01 Sep 2017 Results published in the American Journal of Hematology
- 23 Aug 2017 New trial record